object
studi
investig
use
chloroquin
clq
antivir
agent
dengu
chloroquin
amin
acidotrop
drug
known
affect
intracellular
exocyt
pathway
increas
endosom
ph
use
vitro
treatment
cell
infect
dengu
viru
type
viral
replic
assess
quantif
viru
produc
detect
copi
number
rna
plaqu
assay
indirect
immunofluoresc
qrtpcr
plaqu
assay
use
quantifi
load
infect
cell
clq
treatment
found
dose
mgml
clq
toxic
cell
result
significantli
less
viru
product
infect
cell
occur
untreat
cell
present
work
clq
effect
replic
cell
also
caus
statist
signific
reduct
express
proinflammatori
cytokin
present
studi
indic
clq
may
use
reduc
viral
yield
cell
enter
target
cell
via
receptormedi
endocytosi
direct
interact
viral
e
glycoprotein
host
cell
receptor
includ
dcspecif
nonintegrin
mannos
receptor
follow
acid
phdepend
fusion
membran
endocyt
vesicl
chloroquin
synthes
first
time
germani
bayer
barmen
leverkusen
germani
prevent
low
phinduc
fusion
viral
envelop
cell
endosom
membran
clq
potenti
abl
block
entri
certain
virus
cytosol
present
studi
examin
effect
clq
replic
mammalian
cell
order
defin
whether
clq
could
use
reduc
viral
yield
studi
carri
strict
accord
brazilian
govern
ethic
anim
experi
regul
procedur
use
anim
research
project
accord
ethic
principl
establish
brazilian
colleg
anim
experiment
experiment
protocol
approv
committe
ethic
anim
experi
univers
sao
paulo
cetea
usp
permit
protocol
number
vero
cell
african
green
monkey
kidney
cell
line
grown
cultur
medium
invitrogen
grand
island
new
york
usa
supplement
fb
lglutamin
mm
penicillin
g
uml
streptomycin
mgml
tryptos
phosphat
vero
cell
maintain
co
aed
albopictu
cell
line
cultur
medium
supplement
fb
lglutamin
tryptos
phosphat
penicillin
g
uml
streptomycin
mgml
absenc
co
suspens
cell
monocyt
lineag
cultur
rpmi
medium
supplement
gl
lglutamin
gl
sodium
bicarbon
mml
hepe
penicillin
g
uml
streptomycin
mgml
fb
invitrogen
maintain
co
parent
new
guinea
c
strain
recov
brain
suckl
swiss
mice
viru
passag
sever
time
cell
contain
cm
cultur
flask
viru
dilut
ml
fb
hr
ml
supplement
fb
ad
cell
cultur
day
cell
cultur
supernat
harvest
centrifug
min
remov
cell
debri
suspens
kept
ice
prevent
microbi
loss
viru
suspens
adjust
fb
divid
aliquot
store
frozen
viru
stock
cell
cultur
supernat
use
present
studi
free
lipopolysaccharid
mycoplasma
viru
product
titrat
plaqu
assay
use
vero
cell
vero
cell
seed
cell
well
plate
medium
fb
hr
medium
remov
decim
serial
dilut
viru
stock
supernat
cell
treat
clq
prepar
medium
fb
ad
mlwell
cell
incub
hr
subsequ
medium
contain
fb
carboxymethylcellulos
mlwell
overlay
ad
plate
incub
day
overlay
remov
day
cell
fix
solut
formaldehyd
pb
hr
room
temperatur
formaldehyd
solut
remov
cell
wash
twice
pb
stain
min
crystal
violet
solut
ethanol
plaqu
cell
lysi
count
viru
concentr
express
pfu
per
ml
cytotox
induc
clq
assay
cell
determin
ideal
concentr
experi
suspens
cell
seed
cellswel
plate
incub
period
approxim
hr
cultur
medium
replac
rpmi
medium
contain
fb
differ
concentr
clq
sigmaaldrich
st
loui
mo
usa
incub
period
hr
drug
cell
remov
viabil
confirm
trypan
blue
exclus
method
invitrogen
indirect
immunofluoresc
assay
perform
determin
presenc
viral
infect
cell
cultur
treat
clq
prepar
slide
immunofluoresc
cell
suspens
centrifug
rpm
min
cell
antivir
activ
chloroquin
wash
twice
pb
place
slide
mlwell
fix
cold
aceton
min
store
slide
incub
hyperimmun
mous
ascit
fluid
dilut
pb
fb
min
humidifi
atmospher
rins
four
time
pb
sampl
similarli
incub
dilut
fluorescein
isothiocyanatelabel
goat
antimous
antibodi
sigmaaldrich
evan
blue
min
rins
four
time
pb
air
dri
wash
coverslip
mount
buffer
glycerin
examin
photograph
use
invert
fluoresc
microscop
fluoresc
foci
locat
within
cm
area
well
count
suspens
cell
cellsml
seed
onto
plate
infect
pfu
ml
moi
hr
postinfect
inoculum
remov
cell
incub
presenc
differ
concentr
clq
mgml
follow
defin
time
interv
differ
experi
concomitantli
hr
infect
ii
concomitantli
hr
infect
interv
day
iii
concomitantli
hr
infect
interv
day
mock
control
replic
contain
clq
infect
cell
supernat
collect
hr
postinfect
clear
centrifug
store
aliquot
use
realtim
pcr
plaqu
assay
experi
carri
duplic
result
shown
mean
valu
obtain
three
individu
experi
viral
rna
extract
ml
supernat
sampl
use
qiaamp
viral
rna
kit
qiagen
valencia
ca
usa
accord
manufactur
instruct
total
rna
extract
trizol
method
guanidinium
thiocyanatephenolchloroform
extract
total
rna
infect
uninfect
cell
treat
untreat
clq
hr
infect
hr
interv
extract
hr
postinfect
use
trizol
reagent
invitrogen
accord
manufactur
instruct
real
time
qpcr
perform
determin
number
rna
copi
present
supernat
describ
previous
briefli
construct
standard
curv
number
particl
produc
infect
cell
measur
number
rna
copi
quantit
qrtpcr
serial
dilut
infect
cell
supernat
qrtpcr
contain
ml
sybr
green
master
mix
reagent
appli
biosystem
foster
ca
usa
ml
rnase
inhibitor
ml
multiscrib
uml
life
technolog
carlsbad
ca
usa
ml
primer
nm
specif
design
anneal
untransl
region
utr
ml
diethylpyrocarbon
water
ml
rna
final
volum
ml
amplif
protocol
consist
follow
step
min
min
follow
cycl
sec
final
min
protocol
use
quantifi
rna
copi
present
supernat
clqtreat
untreat
cell
infect
collect
defin
postinfect
interv
describ
rel
quantif
cytokin
ifna
ifnb
ifng
tnfa
relat
transcript
bactin
gene
endogen
control
perform
use
pcr
reaction
real
time
use
quantitect
sybr
green
pcr
kit
qiagen
reaction
perform
final
volum
ml
contain
ml
cdna
ml
quantitect
sybr
green
pcr
master
mix
hotstartaq
dna
extract
rna
convert
cdna
reaction
revers
transcriptas
enzym
mmlv
invitrogen
accord
manufactur
protocol
prepar
cdna
concentr
hg
total
rna
use
sampl
statist
analysi
use
assess
differ
viral
yield
timedefin
interv
infect
cell
contact
clq
control
cell
without
drug
data
enter
graphpad
prism
softwar
version
submit
oneway
anova
nonparametr
test
analysi
follow
bonferroni
test
cytokin
mrna
quantif
realtim
pcr
test
use
student
ttest
analys
valu
p
consid
statist
signific
concentr
equal
higher
mgml
clq
highli
cytotox
cell
concentr
equal
lower
mgml
clq
induc
signific
cytotox
chloroquin
highli
cytotox
cell
treat
concentr
mgml
wherea
signific
cytotox
observ
cell
treat
concentr
mgml
fig
base
data
clq
use
concentr
mgml
experi
determin
whether
clq
inhibit
replic
suspens
cell
infect
incub
fb
rpmi
medium
contain
differ
concentr
drug
viru
product
quantifi
qrtpcr
plaqu
assay
result
qrtpcr
show
clq
inhibit
replic
cell
dosedepend
manner
fig
viral
replic
cell
significantli
less
addit
mgml
clq
hr
infect
untreat
cell
inhibit
maintain
hr
infect
fig
result
obtain
viru
product
assess
plaqu
assay
result
show
excel
correl
qrtpcr
fig
durat
viral
inhibit
effect
induc
clq
may
relat
time
drug
administr
antivir
effect
clq
analyz
cell
treat
drug
hr
infect
interv
postinfect
qrtpcr
show
treat
cell
produc
significantli
less
viru
untreat
cell
day
infect
fig
assess
plaqu
assay
agreement
qrtpcr
fig
cell
infect
uninfect
viru
presenc
absenc
clq
ad
hr
infect
thereaft
hr
interv
yield
significantli
less
viru
untreat
cell
sixth
day
infect
fig
determin
whether
clq
interf
ifna
ifnb
ifng
tnfa
releas
pretransl
effect
drug
cytokin
mrna
express
investig
realtim
pcr
cell
infect
uninfect
treat
untreat
clq
fig
infect
cell
treatment
clq
downregul
express
proinflammatori
cytokin
ifnb
ifng
tnfa
compar
posit
control
fig
case
ifna
express
inhibit
hour
postinfect
fig
statist
signific
differ
express
antiinflammatori
cytokin
compar
posit
control
fig
addit
antimalari
effect
clq
may
interfer
replic
cycl
mani
virus
interact
viral
entri
mediat
endosom
late
stage
replic
envelop
virus
chloroquin
first
synthes
germani
bayer
emerg
first
half
centuri
effect
substitut
quinin
previou
drug
choic
malaria
multipl
mechan
action
differ
accord
pathogen
weak
base
increas
ph
acid
vesicl
concentr
acid
organel
endosom
lysosom
vesicl
golgi
mechan
involv
proton
pump
requir
energi
increas
ph
last
decad
two
major
mechan
action
clq
well
describ
alkal
acid
vesicl
therebi
interf
endosomemedi
viral
entri
alter
posttransl
modif
protein
newli
synthes
cell
infect
viru
demonstr
antivir
effect
clq
cell
infect
find
agreement
report
faria
et
al
show
vero
cell
infect
treat
clq
hr
postinfect
differ
time
interv
hr
viral
replic
decreas
dose
depend
manner
vitro
studi
demonstr
clq
strong
antivir
effect
virus
hepat
b
viru
herp
simplex
viru
type
influenza
viru
human
immunodefici
viru
sever
acut
respiratori
syndrom
coronaviru
epsteinbarr
viru
vitro
studi
demonstr
therapeut
action
clq
exposur
viru
hr
infect
recent
studi
shown
clq
treatment
inhibit
mtrail
reloc
ifna
product
plasmacytoid
dendrit
cell
one
studi
show
patient
dengu
treat
clq
improv
qualiti
life
abl
resum
daili
activ
tricou
et
al
evalu
effect
clq
adult
patient
dengu
found
treatment
clq
effect
viremia
antigenemia
studi
limit
measur
viremia
quantit
rtpcr
surrog
wellcharacter
marker
infect
though
recogn
quantit
biolog
assay
infecti
viru
vitro
studi
measur
viral
yield
quantit
rtpcr
plaqu
assay
regard
amount
cytokin
cell
cultur
assess
realtim
pcr
found
infect
cell
treat
clq
contain
significantli
less
ifnb
ifng
tnfa
posit
control
fig
clq
reduc
ifna
product
hr
postinfect
drug
reduc
product
proinflammatori
cytokin
interf
mrna
synthesi
ifng
tnfa
ifnb
ifna
van
den
born
et
al
show
clq
decreas
product
proinflammatori
cytokin
infg
tnfa
peripher
blood
mononuclear
cell
stimul
lp
chloroquin
inhibit
releas
tnfa
macrophag
inhibit
synthesi
tnfa
mrna
jang
et
al
show
clq
interfer
product
cytokin
tnfa
monocytesmacrophag
stimul
lp
chloroquin
reportedli
decreas
express
tnfa
receptor
surfac
human
histiocyt
cell
delay
transport
cell
surfac
gandini
et
al
show
clq
treatment
complet
block
ifna
secret
plasmacytoid
dendrit
cell
silva
et
al
show
clqmediat
block
process
partial
inhibit
west
nile
virusinduc
ifna
product
plasmacytoid
dendrit
cell
cultur
result
corrobor
studi
demonstr
clq
interfer
express
proinflammatori
cytokin
postul
reduct
proinflammatori
cytokin
infect
cell
treat
clq
could
due
drug
antiinflammatori
effect
particularli
clq
tnfa
inhibitor
anoth
possibl
mechan
effect
clq
cell
infect
dengu
viru
could
via
antivir
action
decreas
viral
load
thu
degre
immun
system
activ
conclus
therapeut
use
clq
consid
safe
effect
drug
use
treat
mani
diseas
includ
malaria
could
expand
shown
studi
drug
signific
antivir
effect
replic
cell
cultur
chloroquin
well
known
immunomodulatori
agent
data
indic
clq
inhibit
ifna
ifnb
ifng
tnfa
gene
express
infect
treat
clq
studi
support
paulo
foundat
research
fapesp
grant
kj
faria
support
fapesp
fellowship
grant
author
declar
conflict
interest
